Loading...
Market
Will BioAge Labs' IPO valuation exceed $1 billion by end of Q4 2024?
3
BioAge Labs•United States•Eli Lilly•BioAge•a16z•Khosla Ventures•Sofinnova•Longitude Capital•RA Capital•Kristen Fortney•NASDAQ
Resolution / Starting Odds
Yes • 50%
No • 50%
Official NASDAQ filings and press releases
Story
Longevity Biotech BioAge Labs Files for $100 Million US IPO on NASDAQ
Sep 3, 2024, 09:37 PM
BioAge Labs, a clinical-stage biotechnology company developing therapies for obesity and metabolic diseases, has filed for an initial public offering (IPO) in the United States. The company, which is collaborating with Eli Lilly on obesity therapy, aims to raise $100 million through the IPO. This move follows BioAge's successful $170 million funding round in February, led by prominent investors including a16z, Khosla Ventures, Sofinnova, Longitude Capital, and RA Capital. BioAge's lead asset is azelaprag, an orally available small molecule agonist of the apelin receptor, currently in Phase 2 trials. The company is also working on early-stage NLRP3 inhibitors. BioAge, led by CEO Kristen Fortney, will be listed on NASDAQ and is considered a significant player in the longevity biotech sector.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Below $1 billion • 25%
$1 billion to $2 billion • 25%
$2 billion to $3 billion • 25%
Above $3 billion • 25%
Above $1 billion • 25%
Between $750 million and $1 billion • 25%
Between $500 million and $750 million • 25%
Below $500 million • 25%
Above $25 • 25%
Between $20 and $25 • 25%
Between $15 and $20 • 25%
Below $15 • 25%
Above $100 million • 25%
Between $50 million and $100 million • 25%
Between $10 million and $50 million • 25%
Below $10 million • 25%
Yes • 50%
No • 50%
